Project Grant R41EY038621
Award Date 9/15/26
Completion Date 8/31/27
Dollars Obligated $290K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Huntsville, AL 35806, USA
Similar Awards
- The National Eye Institute awarded Neovascularx, Inc. $305,321 on September 30, 2025, under the Vision Research program (CFDA 93.867) to clinically develop and commercialize topical ophthalmic products for treating neovascular age-related macular degeneration (NAMD). The project focuses on developing a home-based topical treatment alternative to existing monthly or bimonthly intravitreous injections of VEGF inhibitors. Current injectable therapies, while effective, present significant challenges...
- The National Eye Institute awarded Baylor College of Medicine $646,167 on April 1, 2026, for investigations of cellular and molecular mechanisms underlying age-related macular degeneration (AMD) under the Vision Research program (CFDA 93.867). The project applies high-throughput functional genomics approaches to test whether non-coding risk variants in AMD exert their effects through gene expression regulation enriched within specific functional networks in disease-relevant tissues. The work...
- The National Eye Institute awarded the University of Rochester a $2,215,463 cooperative agreement on March 17, 2026, under the Vision Research program (CFDA 93.867) to develop small molecule PROTAC compounds targeting secretory phospholipase A2-IIA (SPLA2-IIA) for treatment of age-related macular degeneration and related macular dystrophies. The award funds development of proteolysis-targeting chimera compounds designed to induce degradation of SPLA2-IIA, a pro-inflammatory enzyme identified...
- The National Eye Institute awarded Vanderbilt University Medical Center $714,844 on September 1, 2026, under the Vision Research program (CFDA 93.867) to develop enabling technologies for pre-clinical and translational research using three-dimensional adult retina tissue culture. The award funds three technical aims: development of a custom scalable microfluidic platform integrated into air-liquid interface culture format to stabilize retinal tissue culture conditions and enable programmable...
- The National Eye Institute awarded Baylor College of Medicine $487,986 on September 1, 2026, under the Vision Research program (CFDA 93.867) to dissect retinal glial regulatory mechanisms and refine age-related macular degeneration risk loci through high-throughput functional genomics. The research applies innovative genomics approaches to test the hypothesis that retinal glial function is modulated by AMD risk variants in genes enriched within specific functional networks. The work addresses...
- The National Eye Institute awarded The Research Foundation For The State University Of New York $248,737 on June 1, 2026, under the Vision Research program (CFDA 93.867) to support research on the role of mitochondrial and autophagy dysfunction in regulating inflammatory processes during age-related macular degeneration pathogenesis. The award funds investigation into the deregulation of autophagy and heightened inflammation implicated in dry AMD, the leading cause of blindness in the elderly...
- The National Eye Institute awarded The Leland Stanford Junior University $666,976 on August 1, 2026, under the Vision Research program (CFDA 93.867) to map age-related macular degeneration (AMD) using precision proteomics and molecular aging analysis. The recipient will deploy the TEMPO (Tracing Expression of Multiple Protein Origins) platform to profile protein biomarkers and identify cellular drivers of AMD in living patients using human liquid biopsy samples. TEMPO integrates aptamer-based...
- The National Eye Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $733,137 to the University of California, Los Angeles on September 15, 2025, under the Vision Research program (CFDA 93.867) to explore how genetic variation influences disease progression and therapeutic response in age-related macular degeneration. The project integrates advanced optical coherence tomography imaging with machine learning and artificial intelligence to classify...
- The National Eye Institute awarded the University of Rochester $684,914 on July 1, 2026, under the Vision Research program (CFDA 93.867) to develop human induced pluripotent stem cell (hiPSC)-derived retinal tissue models for disease research and cell-based therapeutic applications. The award funds two complementary aims. Aim 1 develops a microphysiological model of comprehensive hiPSC-derived retina that emulates the physiological spherical geometry of the human retina in vivo, suitable for...
- The National Eye Institute awarded Oregon Health & Science University $860,190 on February 6, 2026, to develop and test hypoimmune retinal pigment epithelial (RPE) cell transplants designed to survive, engraft, and evade immune rejection in nonhuman primates as a model for treating advanced dry age-related macular degeneration (AMD). The project addresses a critical gap in AMD treatment. Current RPE cell transplant therapies in animal models and early clinical trials require chronic...